1
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: infections, Modified 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, December 22, 2009: US07635689 (47 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compos ...


2
Storer Richard, Gosselin Gilles, Dukhan David, Leroy Frédéric: Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c. Idenix, Centre National de La Recherche Scientifique, L Universite Montpellier Ii, Storer Richard, Gosselin Gilles, Dukhan David, Leroy Frédéric, MARSHALL Cameron John, February 3, 2005: WO/2005/009418 (45 worldwide citation)

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optio ...


3
Sommadossi Jean Pierre, Gosselin Gilles, Pierra Claire, Perigaud Christian, Peyrottes Suzanne: Compounds and pharmaceutical compositions for the treatment of viral infections. Idenix Pharmaceuticals, Centre National de La Recherche Scientifique, L Universite Montpellier Ii, Sommadossi Jean Pierre, Gosselin Gilles, Pierra Claire, Perigaud Christian, Peyrottes Suzanne, PATHAK Rahul, July 10, 2008: WO/2008/082601 (33 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.


4
Jean Louis Imbach, Martin L Bryant, Gilles Gosselin: 3′-prodrugs of 2′-deoxy-β-L-nucleosides. Idenix Pharmaceuticals, CNRS, L Universite Montpellier II, Sherry M Knowles Esq, King & Spalding, April 5, 2005: US06875751 (27 worldwide citation)

The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3′-esters of 2′-deoxy-β-L-nucleosides are disclosed, which can be administered either alone or in combination with other anti ...


5
Gilles Gosselin, Richard Storer, Paola LaColla, Jean Pierre Sommadossi: infections, 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, December 1, 2009: US07625875 (26 worldwide citation)

2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior resu ...


6
Jean Pierre Sommadossi, Paolo LaColla, Gilles Gosselin: 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. Idenix Pharmaceuticals, University of Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, September 1, 2009: US07582618 (23 worldwide citation)

The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include ...


7
Gilles Gosselin, Jean Louis Imbach, Martin L Bryant: β-L-2′-deoxy-nucleosides for the treatment of hepatitis B. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, L Universite Montpellier II, Sherry M Knowles, King & Spalding, September 20, 2005: US06946450 (19 worldwide citation)

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-p ...


8
Paola LaColla, Jean Pierre Sommadossi, Gilles Gosselin: infections, 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, University of Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, February 16, 2010: US07662798 (16 worldwide citation)

2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior resu ...


9
Martin L Bryant, Gilles Gosselin, Jean Louis Imbach: 3′-prodrugs of 2′-deoxy-β-L-nucleosides. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, September 8, 2009: US07585851 (12 worldwide citation)

The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3′-esters of 2′-deoxy-β-L-pyrimidine nucleosides are disclosed, which can be administered either alone or in combination with ...


10
Sommadossi Jean Pierre, Gosselin Gilles, Pierra Claire, Perigaud Christian, Peyrottes Suzanne: Compounds and pharmaceutical compositions for the treatment of liver disorders. Idenix Pharmaceuticals, Centre National de La Recherche Scientifique, L Universite Montpellier Ii, Sommadossi Jean Pierre, Gosselin Gilles, Pierra Claire, Perigaud Christian, Peyrottes Suzanne, PATHAK Rahul, July 10, 2008: WO/2008/082602 (9 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including liver cancer and metabolic diseases, such as diabetes, hyperlipidemia, atherosclerosis, and obesity. Specifically, compounds and compositions of nucleoside derivatives are disclosed, which can be ...